ADMA Biologics, Inc. (NASDAQ: ADMA),changed 5.01% to recent value of $3.77. The stock transacted 924095 shares during most recent day however it has an average volume of 988.91K shares. It spotted trading -45.83% off 52-week high price. On the other end, the stock has been noted 81.25% away from the low price over the last 52-weeks.

ADMA Biologics, Inc. (NASDAQ: ADMA), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, reported the United States Food and Drug Administration (“FDA”) has notified ADMA the licenses for BIVIGAM® and Nabi-HB® have been revoked from Biotest Pharmaceuticals Corporation, (“BPC”) U.S. License No. 1792 and transferred and issued to ADMA’s U.S. License No. 2019.

President and Chief Executive Officer, Adam Grossman stated “We are very pleased to announce the U.S. License transfer of BIVIGAM® and Nabi-HB® from BPC to ADMA, as this was the final remaining regulatory item from the acquisition of the Biotest Therapy Business Unit transaction”.  “It is important for patients, prescribers and investors to recognize that FDA regulatory licensing is complex, particularly with respect to ADMA’s acquisition of the BTBU assets.  Since ADMA’s ownership and operation of the BTBU, we have received an acceptable FDA inspection classification, FDA approvals for two product submissions and now licenses issued in ADMA’s name for two FDA approved biologic drugs.  FDA’s license transfer of BIVIGAM® and Nabi-HB® to ADMA’s U.S. License 2019 constitutes a determination by FDA that the establishment and the products meet applicable requirements to ensure the continued safety, purity, and potency of the products.  Those applicable requirements also include FDA’s current Good Manufacturing Practice (“cGMP”).  Going forward, ADMA will manufacture and introduce both BIVIGAM® and Nabi-HB® into interstate commerce under ADMA’s U.S. License No. 2019 along with its recently approved patented Immune Globulin, ASCENIV®.”

ADMA . Its earnings per share (EPS) expected to touch remained 23.90% for this year .

The company has 55.66M of outstanding shares and 46.48M shares were floated in the market. According to the most recent quarter its current ratio was 4.6 that represents company’s ability to meet its current financial obligations. The price moved ahead of 1.60% from the mean of 20 days, -10.17% from mean of 50 days SMA and performed -14.08% from mean of 200 days price. Company’s performance for the week was -2.58%, 0.00% for month and YTD performance remained 57.74%.